Citations

Showing 10 of 108104 citations.

Turning a Page in the Yellow Journal: Figure Legends and Gender-Inclusive Patient Descriptors
Doo, Florence X., Zavaletta, Vaz, Carroll, Evelyn F., Ellis, Keri L., Rosenkrantz, Andrew B., Doo, Florence Xini , Zavaletta, Vaz, Carroll, Evelyn F., Ellis, Keri L., Rosenkrantz, Andrew B.

Mayo Clinic

American Journal of Roentgenology | April 13, 2022 | Volume: 219 | Issue: 1 | Pages: 1-2

10.2214/ajr.22.27536 | PMID 35417186 Get It

Incidence of Monomicrobial Staphylococcus aureus Bacteremia: A Population-Based Study in Olmsted County, Minnesota—2006 to 2020
Hindy, Joya Rita, Lahr, Brian D. , Palraj, Raj , Saleh, Omar Abu , Arshad, Verda , Talha, Khawaja M. , Quintero-Martinez, Juan A , Palraj, Raj , Go, John R, Fida, Madiha , Abu Saleh, Omar M, Sohail, M Rizwan , Hindy, Joya-Rita , Quintero-Martinez, Juan Andres , Go, John Raymond , DeSimone, Daniel C. , Sohail, M. Rizwan , Baddour, Larry M.

Mayo Clinic

Open Forum Infectious Diseases | April 13, 2022 | Volume: 9 | Issue: 7 | Pages: No page available

10.1093/ofid/ofac190 | PMID 35794939 Get It

Abstract Background Population-based studies of Staphylococcus aureus bacteremia (SAB) in the United States are limited. We provide a contemporary evaluation of SAB incidence in Olmsted County, Minnesota, from 2006 to 2020. Methods This was a retrospective population-based study of all adult patients with SAB residing in Olmsted County from 1 January 2006 through 31 December 2020. Initial episodes of SAB were identified using the microbiology laboratory databases at both Olmsted Medical Center and Mayo Clinic Rochester. Results Overall, 541 incident SAB cases were identified with a median age of 66.8 (interquartile range, 54.4–78.5) years, and 60.4% were male. Among these cases, 298 (56.2%) were due to methicillin-susceptible S aureus (MSSA) and 232 (43.8%) cases of methicillin-resistant S aureus (MRSA). The overall age- and sex-adjusted SAB incidence rate (IR) was 33.9 (95% confidence interval [CI], 31.0–36.8) cases/100 000 person-years (PY). Males had a higher age-adjusted IR of 46.0 (95% CI, 41.0–51.0) cases/100 000 PY compared to females (IR, 24.4 [95% CI, 21.1–27.7] cases/100 000 PY). Age- and sex-adjusted SAB IRs due to MSSA and MRSA were 18.7 and 14.6 cases/100 000 PY, respectively, and the percentage of incident SAB cases due to MRSA fluctuated across the study period. There was no apparent temporal trend in SAB incidence over the study period (P = .093). Conclusions Our investigation represents the only contemporary population-based study in the United States. Despite the impression that SAB incidence may have increased based on Centers for Disease Control and Prevention surveillance data, our finding of no change in SAB incidence was somewhat unanticipated.
Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Li, Xuanyi , Beeghly‐Fadiel, Alicia , Tavana, Hossein , Rubinstein, Samuel M. , Fernandes, Hermina, Riaz, Irbaz Bin , Bhavnani, Suresh K. , Gyawali, Bishal , Warner, Jeremy L.

Mayo Clinic

JAMA Network Open | April 13, 2022 | Volume: 5 | Issue: 4 | Pages: e224361

10.1001/jamanetworkopen.2022.4361 | PMID 35416993 Get It

Political Campaign Contributions of Surgeons in the United States Throughout the 2020 Election Cycle
Mehra, Mehul , Wang, Kendra, Sherman, Benjamin C. , Gopali, Rhea , Deme, Palvasha , Hoyt, David B., Barpujari, Awinita , Singh, Rohin , Reddy, Vamsi P.

Mayo Clinic

JAMA Surgery | April 13, 2022 | Volume: 157 | Issue: 6 | Pages: 515

10.1001/jamasurg.2022.0798 | PMID 35416934 Get It

Facial Soft Tissue Repositioning With Neuromodulators: Lessons Learned From Facial Biomechanics
Hernandez, Claudia A, Davidović, Kristina , Alfertshofer, Michael , Freytag, David L., Frank, Konstantin , Bihun, Rebekah , Cotofana, Sebastian , Velthuis, Peter J. , Alfertshofer, Michael , Cotofana, Sebastian , Avelar, Luiz Eduardo Toledo , Frank, Konstantin , Moellhoff, Nicholas , Green, Jeremy B. , Bihun, Rebekah J.

Mayo Clinic

Aesthetic Surgery Journal | April 13, 2022 | Volume: 42 | Issue: 10 | Pages: 1163-1171

10.1093/asj/sjac090 | PMID 35416929 Get It

Abstract Background Neuromodulators have proven efficacy in reducing facial rhytides and have also been reported to improve jawline contour and the appearance of platysmal bands. Lifting effects of the tail of the eyebrow are expected outcomes when targeting the lateral periorbital region, underscoring the versatility of neuromodulator treatments. Objectives The aim of this study was to analyze the clinical effectiveness of a novel neuromodulator-based injection algorithm with regards to its ability to reposition the middle and lower facial soft tissues. Methods Seventy-five study participants (8 males, 67 females) with a mean [standard deviation] age of 37.5 [8.5] years were injected with neuromodulators in the subdermal plane of the mandibular soft tissues following a standardized algorithm. Live rating of clinical appearance was performed, as well as volume change and skin vector displacement measured by 3-dimensional imaging at baseline, Day 14, and Day 30. Results Three-dimensional volume analysis revealed an increase in midfacial volume by 0.46 mL, and a decrease of the lower facial volume by 0.30 mL compared with baseline. Additionally, an improvement of midfacial fullness (by 0.13) and jawline contour (by 0.44) was reported on clinical rating scales at Day 30 compared with baseline. Conclusions Facial soft tissues can be repositioned during the 30-day follow-up period following a neuromodulator treatment; this was reflected through an increase in midfacial volume as well as through a decrease in lower facial volume. The novel injection algorithm presented can provide a safe and effective option for patients desiring improvement of midfacial fullness and jawline contour with neuromodulator treatment alone. Level of Evidence: 4
Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice
Evgin, Laura , Kottke, Tim , Tonne, Jason M., Thompson, Jill , Huff, Amanda L. , Vloten, Jacob P. van , Moore, Madelyn , Michael, Josefine, Driscoll, Christopher B. , Pulido, José S. , Swanson, Eric , Kennedy, Richard B. , Loghmani, Houra , Sánchez-Pérez, Luis, Olivier, Gloria , Harrington, Kevin J. , Pandha, Hardev , Melcher, Alan , Díaz, Rosa María, Vile, Richard G. , Tonne, Jason , van Vloten, Jacob , Driscoll, Christopher , Pulido, Jose, Kennedy, Richard , Coffey, Matt C. , Olivier, Gloria , Harrington, Kevin , Melcher, Alan A , Swanson, Eric

Mayo Clinic

Science Translational Medicine | April 13, 2022 | Volume: 14 | Issue: 640 | Pages: No page available

10.1126/scitranslmed.abn2231 | PMID 35417192 Get It

Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells in the solid tumor microenvironment (TME). Here, using systemically delivered OVs and CAR T cells in immunocompetent mouse models, we have defined a mechanism by which OVs can potentiate CAR T cell efficacy against solid tumor models of melanoma and glioma. We show that stimulation of the native T cell receptor (TCR) with viral or virally encoded epitopes gives rise to enhanced proliferation, CAR-directed antitumor function, and distinct memory phenotypes. In vivo expansion of dual-specific (DS) CAR T cells was leveraged by in vitro preloading with oncolytic vesicular stomatitis virus (VSV) or reovirus, allowing for a further in vivo expansion and reactivation of T cells by homologous boosting. This treatment led to prolonged survival of mice with subcutaneous melanoma and intracranial glioma tumors. Human CD19 CAR T cells could also be expanded in vitro with TCR reactivity against viral or virally encoded antigens and was associated with greater CAR-directed cytokine production. Our data highlight the utility of combining OV and CAR T cell therapy and show that stimulation of the native TCR can be exploited to enhance CAR T cell activity and efficacy in mice.
Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study
Tome, June , Sehgal, Kanika , Kamboj, Amrit K. , Comstock, Bryce, W, Scott Harmsen, Khanna, Sahil , Pardi, Darrell S. , Tome, June

Mayo Clinic

American Journal of Gastroenterology | April 13, 2022 | Volume: 117 | Issue: 8 | Pages: 1311-1315

10.14309/ajg.0000000000001774 | PMID 35417427 Get It

INTRODUCTION: Outcomes and safety of budesonide maintenance therapy in microscopic colitis (MC) are not well known. METHODS: Adult residents of Olmsted County, Minnesota, diagnosed with MC (2002–2019) and treated with budesonide were identified using the Rochester Epidemiology Project. Response was assessed at 12 ± 4 weeks after initiation of therapy and defined as complete (resolution of diarrhea), partial (≥50% improvement in the number of bowel movements), nonresponse (<50% improvement), and intolerance (discontinued because of side effects). For safety outcomes, cases (budesonide maintenance) and MC controls (no budesonide therapy) were matched by sex and age at diagnosis (±2 years). RESULTS: A total of 450 patients were identified, of whom 162 (36.0%) were treated with budesonide for induction of clinical remission (median age 67 [23–91] years and 126 women [77.8%] ). Clinical outcomes for induction were as follows: 130 (80.2%) complete response, 22 (13.6%) partial response, 8 (4.9%) no response, and 2 (1.2%) intolerance. After induction, 96 (63.2%) had recurrence after discontinuation, of whom 27 (28.1%) required further budesonide induction treatment without maintenance, 56 (58.3%) required long-term budesonide maintenance, and 13 (13.5%) were treated with other therapies. Of those receiving budesonide maintenance, all responded (55 [98.2%] complete and 1 [1.8%] partial). No patient stopped maintenance from adverse events. The median duration of follow-up was 5.6 years (0.3–18.9). There was no significant difference between cases and controls in the incidence of osteopenia/osteoporosis, diabetes mellitus, hypertension, glaucoma, or cataracts. DISCUSSION: The long-term use of budesonide in MC seems to be effective and generally well tolerated with limited adverse effects.
Ultrasound-Guided Hydrodissection of the Superficial Peroneal Nerve for Chronic Neuropathic Pain: A War Veteran’s Story
Ferreira‐Silva, Nuno , Galacho, João , Ferreira‐Dos‐Santos, Guilherme , Clendenen, Steven R. , Hurdle, Mark Friedrich B., Ferreira-Silva, Nuno

Mayo Clinic

Pain Management | April 13, 2022 | Volume: 12 | Issue: 5 | Pages: 579-586

10.2217/pmt-2022-0014 | PMID 35416721 Get It

Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
Dulai, Parambir S. , Raffals, Laura E. , Kochhar, Gursimran , Damas, Oriana M. , Sauk, Jenny , Levy, Alexander N., Sofia, M. Anthony , Tuskey, Anne , Deepak, Parakkal , Yarur, Andrés , Afzali, Anita , Deepak, Parakkal , Yarur, Andres J , Rai, Victoria , Lukin, Dana J. , Hudesman, David , Ananthakrishnan, Ashwin N. , Cross, Raymond K. , Hanauer, Stephen B. , Siegel, Corey A

Mayo Clinic

American Journal of Gastroenterology | April 13, 2022 | Volume: 117 | Issue: 8 | Pages: 1288-1295

10.14309/ajg.0000000000001775 | PMID 35416799 Get It

INTRODUCTION: Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares. METHODS: RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid dosing, discharge criteria, follow-up, and postdischarge biologic or small molecule initiation. A literature review informed on the panel's voting, which occurred anonymously during 2 rounds before and after a moderated virtual session. RESULTS: Methylprednisolone 40–60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has resolved (Mayo subscore 0–1) and/or stool frequency has returned to baseline frequency and form (Mayo subscore 0–1). It is appropriate to discharge patients on 40 mg of prednisone after observing patients for 24 hours in hospital to ensure stability before discharge. For patients being discharged on steroids without in-hospital biologic or small molecule therapy initiation, it is appropriate to start antitumor necrosis factor (TNF) therapy after discharge for anti-TNF-naive patients. For anti-TNF-exposed patients, it is appropriate to start vedolizumab or ustekinumab for all patients and tofacitinib for those with a low risk of adverse events. It is appropriate to follow up patients clinically within 2 weeks and with lower endoscopy within 4–6 months after discharge. DISCUSSION: We provide recommendations on the inpatient and postdischarge management of patients with ulcerative colitis hospitalized for moderate-severe flares.
Editorial Comment: What Is Prostate MRI Interpretation Experience?
Yano, Motoyo

Mayo Clinic

American Journal of Roentgenology | April 13, 2022 | Volume: 219 | Issue: 3 | Pages: 461-461

10.2214/ajr.22.27781 | PMID 35416059 Get It